Greenwave's 15min chart triggers bullish signal with KDJ Golden Cross, Bullish Marubozu.
PorAinvest
viernes, 12 de septiembre de 2025, 1:31 pm ET1 min de lectura
GWAV--
Over the past month, shares of Pfizer have depreciated by 2.35%, underperforming the Medical sector's gain of 6.01% and the S&P 500's gain of 2.38%. Market participants will be closely following Pfizer's upcoming earnings report, with analysts expecting earnings of $0.79 per share, a year-over-year decline of 25.47%. Revenue is expected to be $17.18 billion, showing a 2.95% drop compared to the year-ago quarter [1].
For the entire year, Zacks Consensus Estimates forecast earnings of $3.13 per share and revenue of $63.81 billion, indicating changes of +0.64% and +0.29%, respectively, compared to the previous year [1].
Investors should also note recent changes to analyst estimates for Pfizer. Positive estimate revisions reflect optimism about the business and profitability. The Zacks Rank, an exclusive model that considers these estimated changes, currently rates Pfizer as a #3 (Hold) [1].
In terms of valuation, Pfizer is trading at a Forward P/E ratio of 7.86, a discount compared to its industry average Forward P/E of 14.14. The company's PEG ratio of 0.87 is also lower than the industry average of 1.57 [1].
The Large Cap Pharmaceuticals industry, which includes Pfizer, has a Zacks Industry Rank of 159, placing it in the bottom 36% of all 250+ industries. The Zacks Industry Rank evaluates the power of distinct industry groups by determining the average Zacks Rank of individual stocks forming the groups [1].
PFE--
The 15-minute chart for Greenwave has recently experienced a Golden Cross of the KDJ indicator, coupled with a Bullish Marubozu at 09/12/2025 13:15. This suggests a shift in momentum towards the upside, with potential for further price appreciation. The control of buyers in the market indicates a likely continuation of bullish momentum.
In the latest trading session, Pfizer (PFE) closed at $24.83, marking a +1.04% move from the previous day. This performance outpaced the S&P 500's daily gain of 0.85%, while the Dow rose by 1.36% and the tech-heavy Nasdaq appreciated by 0.72% [1].Over the past month, shares of Pfizer have depreciated by 2.35%, underperforming the Medical sector's gain of 6.01% and the S&P 500's gain of 2.38%. Market participants will be closely following Pfizer's upcoming earnings report, with analysts expecting earnings of $0.79 per share, a year-over-year decline of 25.47%. Revenue is expected to be $17.18 billion, showing a 2.95% drop compared to the year-ago quarter [1].
For the entire year, Zacks Consensus Estimates forecast earnings of $3.13 per share and revenue of $63.81 billion, indicating changes of +0.64% and +0.29%, respectively, compared to the previous year [1].
Investors should also note recent changes to analyst estimates for Pfizer. Positive estimate revisions reflect optimism about the business and profitability. The Zacks Rank, an exclusive model that considers these estimated changes, currently rates Pfizer as a #3 (Hold) [1].
In terms of valuation, Pfizer is trading at a Forward P/E ratio of 7.86, a discount compared to its industry average Forward P/E of 14.14. The company's PEG ratio of 0.87 is also lower than the industry average of 1.57 [1].
The Large Cap Pharmaceuticals industry, which includes Pfizer, has a Zacks Industry Rank of 159, placing it in the bottom 36% of all 250+ industries. The Zacks Industry Rank evaluates the power of distinct industry groups by determining the average Zacks Rank of individual stocks forming the groups [1].
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema
SOBRE NOSOTROS
Nuestra historiaAutores de noticiasBase de conocimientosPolítica de privacidadTérmino de usoDescargo de responsabilidad de corretaje de tercerosTérminos de uso de AIMEDivulgaciones de riesgos de AInvest AICarrerasCONTÁCTENOS
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comentarios
Aún no hay comentarios